Table 1.

Basic characteristics of patients with NCRNNELM

Characteristics	N (%)
Patients (number)	114
Sex: female	90 (78%)
Age (years), median[range], > 60 years)	55[26–83], 37%
BMI mean (range)	24.6 (16.8–38.7)
ASA 1–2	89 (78.1%)
Primary tumor sites
Breast	70 (61%)
Genito-urinary	13 (11%)
Gastro-intestinal	10 (9%)
Sarcoma	11 (10%)
Melanoma	4 (4%)
Squamous	3 (3%)
Others	3 (3%)
Primary lymph node metastasis	46 (40%)
Timing of diagnosis
0–12 months	43 (38%)
12–24 months	13 (11%)
> 24 months	58 (51%)
Number of nodules mean (median[range])	1.86 [1 (1–9)]
Multi-nodular	62 (54%)
Size of largest nodule mean (median[range]) (mm)	32.85[25 (2–70)]
Size > 50 mm	23 (20%)
Systemic treatment for the primary tumor
NACT	42 (37%)
ACT	79 (69%)
Hormonal therapy	56 (49%)
Radiotherapy	55 (48%)
Trastuzumab	25 (22%)
Glivec	9 (8%)
Other	3 (3%)
Systemic treatment for liver metastases
NACT	95 (83%)
ACT	66 (58%)
Type of surgery
Open approach/laparoscopy	79 (69%)/35 (31%)
RF	33 (29%)
Major hepatectomy	23 (20%)
Complications Clavien-Dindo
0	91 (80%)
I–II	10 (9%)
III (a-b)	12 (11%)
IV	1 (1%)
V	0
Relapse	65 (57%)
Liver	37 (33%)
Liver + lung	3 (3%)
Liver + bone	3 (3%)
Liver + brain	2 (2%)
Liver + peritoneum	3 (3%)
Lung	4 (4%)
Peritoneum	3 (3%)
Bone	1 (1%)
Brain	1 (1%)
Multiple	8 (7%)
Number of hepatectomies
2	11 (10%)
3	1 (1%)
AFC score
1	16 (14%)
2	19 (17%)
3	33 (29%)
4	25 (22%)
5	16 (14%)
6	5 (4%)
Low/ Intermediate risk AFC score	68 (60%)/46 (40%)
mCRS
0	24 (21%)
1	38 (33%)
2	26 (23%)
3	23 (20%)
4	3 (3%)
Low-/high-risk (0–2)	88 (77%)/26 (23%)

BMI body mass index, ASA American Society of Anesthesia, LN lymph node, ACT adjuvant chemotherapy, NACT neoadjuvant chemotherapy, RF radiofrequency destruction, mCRS modified clinical risk score